The pathology market is shifting from traditional glass slides to whole-slide imaging, cloud-based image management, AI-driven analysis, and digitally enabled diagnostics, fueling growth and collaboration among pathologists.

As of 2025, North America accounted for about 40% of the market, while Asia-Pacific is poised for the fastest growth through 2035 due to laboratory modernization and digital transformation.

Regional dynamics show North America at around 40%, Europe 29%, Asia-Pacific 22%, Latin America 5%, and the Middle East & Africa 4% in 2025, shaped by infrastructure investment and digitalization efforts.

Roche announced a plan to acquire PathAI for up to US$1.05 billion (US$750 million upfront, up to US$300 million in milestones) to strengthen AI-driven diagnostics.

Leading players include Leica Biosystems, Roche Diagnostics, Philips Healthcare, Hamamatsu, Fujifilm, Konica Minolta, Carl Zeiss Meditec, Sectra, PathAI, Paige AI, Indica Labs, Proscia, Visiopharm, among others, with market shares such as Leica ~16%, Roche ~12%, Philips ~10%.

In 2026, notable developments include FDA clearances for Proscia Concentriq AP-Dx and Leica Biosystems’ AI-assisted capabilities, plus acquisitions and collaborations to expand end-to-end digital pathology offerings.

AI-powered image analysis and whole-slide imaging are central to the field, with WSI leading market share (about 39.3% by 2025) and AI analysis expected to grow the fastest.

End-use applications cover clinical diagnostics, telepathology, drug discovery, and education across hospitals, diagnostic labs, academic and research institutes, veterinary clinics, and more.

The global digital pathology market was $1.33 billion in 2025 and is projected to reach $6.82 billion by 2035, expanding at roughly an 18.4% CAGR from 2026 to 2035.

Growth drivers include rising cancer incidence, broader AI adoption in pathology, lab digitalization, demand for remote diagnostics, and the expansion of biomarker-driven precision medicine.

Industry developments emphasize AI-powered image analysis, ongoing WSI enhancements, cloud platforms, system integrations, strategic partnerships, and regulatory expansion to support broader clinical adoption.